



# Gestational gut microbial remodeling is impaired in a rat model of preeclampsia superimposed on chronic hypertension

Jeanne A. Ishimwe, Adesanya Akinleye, Ashley C. Johnson, Michael R. Garrett, and Jennifer M. Sasser

Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS



## Introduction


- Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and fetal morbidity.
- It affects 2-8% of all pregnancies, and its pathophysiology is not fully understood.
- Recent studies in preeclamptic patients have suggested a role for the gut microbiome (GM) in the disease.
- In addition, emerging evidence from both human and animal studies have reported that short-chain fatty acids (SCFAs) and other gut-derived metabolites such as lactate may modulate blood pressure.
- We have previously characterized the Dahl salt sensitive rat (Dahl S), a known genetic model of hypertension and kidney disease, as a spontaneous model of preeclampsia superimposed on chronic hypertension.

## Hypothesis


We hypothesized that preexisting chronic hypertension impairs maternal gut microbial remodeling contributing to the development of superimposed preeclampsia.

## Protocol

- Female Sprague Dawley (SD) and Dahl S (SS/jr) rats were maintained in conventional caging in the same room and on the same diet (Teklad 7034, 0.3% NaCl). Half of the rats of each strain were mated to have pregnant and virgin groups (n=7-9/group).
- Fecal samples were collected at baseline (BL), early (D6), mid (D13), late pregnancy (D20) and one-week postpartum (D28) to assess gut microbiome composition via 16S rRNA gene sequencing.
- Differential abundance analysis of  $\alpha$ -diversity was assessed by the Shannon diversity index.
- We used principal coordinates analysis (PCoA) to assess between-subject diversity ( $\beta$ -diversity) in microbial community composition based on a distance matrix of microbial abundance (Bray-Curtis).
- Linear discriminate analysis effect size (LEfSe) analysis was performed to identify the taxa characterizing the differences among groups.
- PICRUSt (phylogenetic investigation of communities by reconstruction of unobserved states) was used to predict functional potential.



**Figure 1. Dahl S and SD have distinct taxonomic composition and phylogenetic diversity.** (A) Baseline Alpha diversity presented as Shannon index. (B) PCoA plot representing baseline beta-diversity. The distance between the two clusters indicates that the microbial population is significantly distinct between strains. (C) Changes in the beta-diversity during pregnancy, PCoA plots representing  $\beta$ -diversity during late pregnancy, day 20. Each dot represents an individual rat.




**Figure 2. Dahl S rats display dysbiosis.** (A) Percent Proteobacteria phylum abundance. (B) Firmicutes to Bacteroidetes ratio.

**Table: Metabolic pathways associated with SCFAs**

Pathway name	Butanoate metabolism	Propanoate metabolism
SD	32 (0.43)	29 (0.57)
Dahl S	33 (0.01)*	31 (0.01)*

Number of gene hits (p-value), \*p<0.05



**Figure 3. LEfSe results representing the differentially abundant genera between Dahl S and SD at baseline.** (A) Genera of good bacteria are significantly more abundant in SD. (B) Genera of pathogenic bacteria are significantly more abundant in Dahl S.

## Conclusions and Future Directions

- The female Dahl S rat exhibits gut dysbiosis outside of pregnancy
- SD rats showed a pregnancy specific increase in Proteobacteria, the Dahl S had no changes in this phylum during pregnancy.
- The SD  $\beta$ -diversity diverged upon pregnancy whereas virgin and pregnant Dahl S remained overlapped.
- The normotensive SD is enriched with beneficial bacteria, and Dahl S enriched with those associated with disease.
- Butanoate and propanoate metabolic pathways may be dysregulated.

Altogether, these data suggest that superimposed preeclampsia may be associated with impaired pregnancy-specific GM changes and dysregulation in SCFA production.

Future studies will investigate the therapeutic potential of supplementation of beneficial SCFAs for the treatment of PE in this model.

## Acknowledgements

This work was performed through the UMMC Molecular and Genomics Facility and supported by AHA20PRE35120561, R01HL137673, and R01HL134711.